Compare US HB 7183 (2024) and US HB 742 (2025)
The introduced text of these two bills, side by side, with the wording they share.
- US HB 7183 (2024) · U.S. Congress · 2024 · Failed
- US HB 742 (2025) · U.S. Congress · 2025 · Pending
464 shared 8-word phrases found in the introduced text of these two bills.
This highlights wording the two bills share in their introduced text. A shared passage may include text that both bills quote from the same existing law, not only language either one drafted. A match shows that the texts overlap; it does not show who drafted a bill, and filing order alone does not show which bill copied which.
| US HB 7183 (2024) | US HB 742 (2025) |
|---|---|
| SESSION H. R. 7183 To prohibit Federal funds from being used to provide certain gender transition procedures to minors. IN THE HOUSE OF REPRESENTATIVES | SESSION H. R. 742 To prohibit Federal funds from being used to provide certain gender transition procedures to minors. IN THE HOUSE OF REPRESENTATIVES |
| introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To prohibit Federal funds from being used to provide certain gender transition procedures to minors. Be it enacted by the Senate and House of Representa- 1 tives of the United States of America in Congress assembled | introduced the following bill; which was referred to the Committee on En- ergy and Commerce A BILL To prohibit Federal funds from being used to provide certain gender transition procedures to minors. Be it enacted by the Senate and House of Representa- 1 tives of the United States of America in Congress assembled |
| VerDate Sep 11 2014 20:57 Feb 06, 2024 Jkt 049200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H7183.IH H | VerDate Sep 11 2014 04:07 Feb 21, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H742.IH H |
| SEC. 2. PROHIBITING FEDERAL FUNDS FROM BEING USED 5 TO PROVIDE CERTAIN GENDER TRANSITION 6 PROCEDURES TO MINORS. 7 (a) IN GENERAL.—Notwithstanding any other provi- 8 sion of law, no Federal funds may be used or otherwise 9 made available to provide or refer for a specified gender 10 transition procedure to an individual under the age of 18 11 or to reimburse any entity for providing such a procedure 12 to such an individual. 13 (b) SPECIFIED GENDER TRANSITION PROCEDURE 14 DEFINED.— 15 (1) IN GENERAL.—For purposes of this para- 16 graph, except as provided in paragraph (2), the term 17 ‘‘specified gender transition procedure’’ means, with 18 respect to an individual, any of the following whe… | SEC. 2. PROHIBITING FEDERAL FUNDS FROM BEING USED 1 TO PROVIDE CERTAIN GENDER TRANSITION 2 PROCEDURES TO MINORS. 3 (a) IN GENERAL.—Notwithstanding any other provi- 4 sion of law, no Federal funds may be used or otherwise 5 made available to provide or refer for a specified gender 6 transition procedure to an individual under the age of 18 7 or to reimburse any entity for providing such a procedure 8 to such an individual. 9 (b) SPECIFIED GENDER TRANSITION PROCEDURE 10 DEFINED.— 11 (1) IN GENERAL.—For purposes of this para- 12 graph, except as provided in paragraph (2), the term 13 ‘‘specified gender transition procedure’’ means, with 14 respect to an individual, any of the following when 15… |
| VerDate Sep 11 2014 20:57 Feb 06, 2024 Jkt 049200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H7183.IH H | VerDate Sep 11 2014 04:07 Feb 21, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H742.IH H |
| viii) metoidioplasty; 5 (ix) penectomy; 6 (x) phalloplasty; 7 (xi) vaginoplasty; 8 (xii) vaginectomy; 9 (xiii) vulvoplasty; 10 (xiv) reduction thyrochondroplasty; 11 (xv) chondrolaryngoplasty; 12 (xvi) mastectomy; and 13 (xvii) any plastic, cosmetic, or aes- 14 thetic surgery that feminizes or 15 masculinizes the facial or other body fea- 16 tures of an individual. 17 (B) Any placement of chest implants to 18 create feminine breasts. 19 (C) Any placement of fat or artificial im- 20 plants in the gluteal region. 21 (D) Administering, supplying, prescribing, 22 dispensing, distributing, or otherwise conveying 23 to an individual medications, including | viii) metoidioplasty; 1 (ix) penectomy; 2 (x) phalloplasty; 3 (xi) vaginoplasty; 4 (xii) vaginectomy; 5 (xiii) vulvoplasty; 6 (xiv) reduction thyrochondroplasty; 7 (xv) chondrolaryngoplasty; 8 (xvi) mastectomy; and 9 (xvii) any plastic, cosmetic, or aes- 10 thetic surgery that feminizes or 11 masculinizes the facial or other body fea- 12 tures of an individual. 13 (B) Any placement of chest implants to 14 create feminine breasts. 15 (C) Any placement of fat or artificial im- 16 plants in the gluteal region. 17 (D) Administering, supplying, prescribing, 18 dispensing, distributing, or otherwise conveying 19 to an individual medications, including |
| VerDate Sep 11 2014 20:57 Feb 06, 2024 Jkt 049200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H7183.IH H | VerDate Sep 11 2014 04:07 Feb 21, 2025 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H742.IH H |
| ii) testosterone, estrogen, or other 5 androgens to an individual at doses that 6 are supraphysiologic than would normally 7 be produced endogenously in a healthy in- 8 dividual of the same age and sex. 9 (2) EXCEPTION.—Paragraph (1) shall not 10 apply to the following when furnished to an indi- 11 vidual by a health care provider with the consent of 12 such individual’s parent or legal guardian: 13 (A) Puberty suppression or blocking pre- 14 scription drugs for the purpose of normalizing 15 puberty for an individual experiencing pre- 16 cocious puberty. 17 (B) Appropriate and medically necessary 18 procedures or treatments to correct for— 19 (i) a medically verifiable genetic dis- 20 order… | ii) testosterone, estrogen, or other 1 androgens to an individual at doses that 2 are supraphysiologic than would normally 3 be produced endogenously in a healthy in- 4 dividual of the same age and sex. 5 (2) EXCEPTION.—Paragraph (1) shall not 6 apply to the following when furnished to an indi- 7 vidual by a health care provider with the consent of 8 such individual’s parent or legal guardian: 9 (A) Puberty suppression or blocking pre- 10 scription drugs for the purpose of normalizing 11 puberty for an individual experiencing pre- 12 cocious puberty. 13 (B) Appropriate and medically necessary 14 procedures or treatments to correct for— 15 (i) a medically verifiable genetic dis- 16 order of… |
| VerDate Sep 11 2014 20:57 Feb 06, 2024 Jkt 049200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\H7183.IH H | VerDate Sep 11 2014 04:07 Feb 21, 2025 Jkt 059200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\H742.IH H |
| mone action, if determined to be abnormal 5 by a physician through genetic or bio- 6 chemical testing; or 7 (iii) infection, disease, injury, or dis- 8 order caused or exacerbated by a previous 9 procedure described in paragraph (1), or a 10 physical disorder, physical injury, or phys- 11 ical illness that would, as certified by a 12 physician, place the individual in imminent 13 danger of death or impairment of a major 14 bodily function unless the procedure is per- 15 formed, not including procedures per- 16 formed for the alleviation of mental dis- 17 tress | mone action, if determined to be abnormal 1 by a physician through genetic or bio- 2 chemical testing; or 3 (iii) infection, disease, injury, or dis- 4 order caused or exacerbated by a previous 5 procedure described in paragraph (1), or a 6 physical disorder, physical injury, or phys- 7 ical illness that would, as certified by a 8 physician, place the individual in imminent 9 danger of death or impairment of a major 10 bodily function unless the procedure is per- 11 formed, not including procedures per- 12 formed for the alleviation of mental dis- 13 tress |
| VerDate Sep 11 2014 20:57 Feb 06, 2024 Jkt 049200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6301 E:\BILLS\H7183.IH H | VerDate Sep 11 2014 04:07 Feb 21, 2025 Jkt 059200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\H742.IH H |